Perifosine News and Research

RSS
Perifosine is a substance that is being studied in the treatment of cancer. Perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.
PS-targeting antibodies can block HIV virus from entering into certain blood cells

PS-targeting antibodies can block HIV virus from entering into certain blood cells

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Unilife's Unitract 1mL Insulin Syringes receive 510(k) market clearance

Unilife's Unitract 1mL Insulin Syringes receive 510(k) market clearance

Chinese SFDA approves Erye Pharmaceutical to manufacture generic Cloxapen

Chinese SFDA approves Erye Pharmaceutical to manufacture generic Cloxapen

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Keryx Biopharmaceuticals reports net loss of $4.7M for 2009 fourth quarter

Keryx Biopharmaceuticals reports net loss of $4.7M for 2009 fourth quarter

BeaconEquity.com announces investment report on AEterna Zentaris

BeaconEquity.com announces investment report on AEterna Zentaris

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris announces 2009 financial and operating results

Decision Resources forecasts multiple myeloma drug market to more than double from $2.1B in 2008 to $5.3B in 2018

Decision Resources forecasts multiple myeloma drug market to more than double from $2.1B in 2008 to $5.3B in 2018

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex

Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine